Advanced Solid Tumor
Conditions
Brief summary
The goal of this phase 1 study is to assess the safety, and tolerability of FP002 to determine the dose recommended for dose expansion in subjects with advanced solid tumor.
Detailed description
This study is a phase 1 study of FP002 as monotherapy in patients with advanced solid tumor. The study will evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile, immunogenicity, and preliminary anti-tumor activity of FP002 in patients with advanced solid tumors.
Interventions
DRUGFP002 Injection
Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
Sponsors
Guangdong Fapon Biopharma Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent form (ICF) and was able to comply with the protocol. 2. Male or female subjects ≥ 18 years of age on the day of ICF signing. 3. A life expectancy of \> 3 months. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 5. Adequate organ and bone marrow function confirmed at screening and within 7 days before the first dose of study treatment. 6. Subjects with histologically or cytological confirmed malignancy diagnosis. 7. Documented advanced solid tumors, defined as patients have no standard treatment or who have failed/are intolerant to standard treatment according to the investigator's judgment. 8. Documented with at least 1 measurable lesion as assessed by RECIST 1.1. 9. Toxicity from prior anti-tumor treatment has resolved to ≤ Grade 1 as defined by NCI CTCAE v5.0.
Exclusion criteria
1. Subjects who have received other anti-CD47 or anti- SIRPα agents. 2. Prior organ or tissue allograft except for hematopoietic stem cell transplantation. 3. Treatment with investigational therapy within 4 weeks prior to initiation of study drug. 4. Severe infection requiring hospitalization or IV antibiotics, antivirals or antifungals within 14 days prior to enrollment. 5. Subjects who have received chemotherapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose (within 6 weeks before the first dose of mitomycin or nitrosoureas) or received immunotherapy, radical radiotherapy or major surgery within 4 weeks or palliative radiotherapy within 2 weeks. 6. Subjects who have experienced active autoimmune disease requiring systemic therapy within the past 2 years. 7. A positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by a certified nucleic acid test within the last 30 days before the first dose of study treatment. 8. Cardiovascular dysfunction or clinically significant cardiac disease. 9. Active infection with hepatitis C. 10. Receipt of a live vaccine within 30 days prior to the first dose of study treatment. 11. Known hypersensitivity to either the drug substances or inactive ingredient of FP002. 12. Known human immunodeficiency virus (HIV) positive. 13. A history of other malignancies other than effectively treated basal cell carcinoma of skin, squamous cell carcinoma of skin, or effectively resected carcinoma in situ of the cervix. 14. Known inherited or acquired bleeding disorders. 15. Any other medical, family, social or mental conditions that the investigator considers unsuitable for participation in the study. 16. Daily requirement for corticosteroids (≥10 mg/kg) within 2 weeks prior to Day 1 of Cycle 1. 17. Women who are lactating or pregnant as confirmed by pregnancy test within 7 days before the first dose of study treatment. Unwilling to use adequate contraceptive methods during the study and for at least 7 months after the last dose of study treatment. 18. Presence of active brain metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity (as graded by CTCAE v5.0) of Dose Limiting Toxicity (DLT) | During the first 4 week treatment cycle |
| Severity (as graded by CTCAE v5.0) of treatment-emergent AEs (TEAEs) | up to 24 months |
| Severity (as graded by CTCAE v5.0) of serious adverse events (SAEs) | up to 24 months |
| Severity (as graded by CTCAE v5.0) of adverse events of special interest (AESIs) | up to 24 months |
| Severity (as graded by CTCAE v5.0) of adverse events assessed | up to 24 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Apparent volume of distribution (Vd) of FP002 | up to 24 months | — |
| Clearance rate (CLz) | up to 24 months | — |
| Terminal elimination rate constant (λz) | up to 24 months | — |
| Mean retention time (MRT) | up to 24 months | — |
| Maximum plasma concentration during the dosing interval at steady state (Cmax,ss) | up to 24 months | — |
| Minimum plasma concentration during the dosing interval at steady state (Cmin,ss) | up to 24 months | — |
| Average steady state concentration (Cav) | up to 24 months | — |
| Steady-state clearance rate (CLss) | up to 24 months | — |
| Steady-state volume of distribution (Vss) | up to 24 months | — |
| Maximum plasma concentration (Cmax) of FP002 | up to 24 months | — |
| Degree of fluctuation (DF) | up to 24 months | — |
| Duration of response (DoR) based on RECIST V1.1 | Up to 24 months | — |
| Disease control rate (DCR) based on RECIST V1.1 | Up to 24 months | — |
| Overall response rate (ORR) based on RECIST V1.1 | Up to 24 months | — |
| Progression free survival (PFS) based on RECIST V1.1 | Up to 24 months | — |
| Anti-drug antibody | Up to 24 months | Incidence, onset time and titer |
| Neutralizing antibody | Up to 24 months | Incidence, onset time and titer |
| Receptor of occupancy in RBC/CD3+ T cell | Up to 24 months | — |
| Accumulation index (Rac) | up to 24 months | — |
| Area under the curve from time zero to the last measurable time point (AUC0-t) of FP002 | up to 24 months | — |
| Area under the curve extrapolated to infinity (AUC0-inf)of FP002 | up to 24 months | — |
| Time to reach maximum plasma concentration (Tmax) of FP002 | up to 24 months | — |
| Terminal elimination half-life (t1/2) of FP002 | up to 24 months | — |
Countries
China
Contacts
Primary ContactArron Wang
Backup ContactVincent Huo
Outcome results
None listed